[Skip to Content]
[Skip to Content Landing]
February 1995

Biochemical Effects of Antidepressant Augmentation

Author Affiliations

Western Psychiatric Institute and Clinic 3811 O'Hara St Pittsburgh, PA 15213

Arch Gen Psychiatry. 1995;52(2):156. doi:10.1001/archpsyc.1995.03950140074012

In their report on the use of pindolol to augment selective serotonin (5-HT) reuptake inhibitors and monoamine oxidase inhibitors, Artigas et al1 suggest that this may be mediated by presynaptic 5-HTIA antagonism, resulting in enhanced serotonergic function. Buspirone, a 5-HTIA agonist, also may be effective in augmenting selective 5-HT reuptake inhibitors in refractory depression.2-5 Because pindolol and buspirone have opposite effects on 5-HTIA function, their efficacy is therefore difficult to reconcile on this basis. Furthermore, it is not clear how 5-HTIA antagonism could account for the effect of pindolol, because reduced sensitivity of presynaptic 5-HTIA receptors is found in major depression.6,7

A major metabolite of buspirone is the α2-adrenergicantagonist 1-(2-pyrimidinyl)-piperazine.8,9α2-Adrenergic antagonism by 1-(2-pyrimidinyl)-piperazine could enhance the release of norepinephrine and result in mood elevation,10 which is consistent with the mechanism of antidepressants such as mianserin11

First Page Preview View Large
First page PDF preview
First page PDF preview